Effect of use of Nasea (ramosetron) and dexamethasone on postoperative recovery in surgery without patient controlled analgesia (PCA) after surgery; Randomized Controlled Trials

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007007

Enrollment

400

Registered

2022-02-18

Start date

2023-03-07

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : # Treatment group: Dexamethasone 5 mg (0.15 mg/kg) iv after induction of anesthesia, and Ramosetron 0.3 mg (6 µg/kg) iv before the end of surgery. # Active Control group: Ramosetron 0.3 mg (6 µ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Patients 19 years of age or older ? Patients managed without Patient Controlled Analgesia (PCA) after surgery ? Type of surgery: general surgery, gynecological surgery, neuro-orthopedic surgery, plastic surgery, otolaryngology surgery ? Patient who signs informed consent (ICF)

Exclusion criteria

Exclusion criteria: ? Under 19 years ? Pregnant or lactating women ? Patients with hypersensitivity to the test drug (dexamethason) ? Patients who have received antiemetics, steroids, antihistamines, etc. or psychotropic drugs that may affect postoperative nausea and vomiting within 24 hours before surgery ? Patients with suspected hepato-renal disorders ? Contraindicated administration of dexamethasone, ramosetron, metoclopramide

Design outcomes

Primary

Measure	Time frame
verbal numerical rating scale (VNRS) was used to evaluate the patient's nausea and vomiting at 6, 12, and 24 hours after surgery.	—

Secondary

Measure	Time frame
PONV incidence by surgery;PONV incidence by risk factor score (age, underlying disease, gender, previous history of nausea and vomiting, medications taken, etc.);Pain control (VAS) between ramosetron versus ramosetron + dexamethasone: reduced VAS compared to baseline;Use of the frequency of rescue drug with ramosetron and ramosetron + dexamethasone;Side effects after drug injection	—

Countries

Korea, Republic of

Contacts

Public ContactYOON JI CHOI

Korea University Ansan Hospital

yoonji07@gmail.com+82-31-412-5289

Outcome results